Bhatt, D L <br/><br/>
The benefit of abciximab in percutaneous coronary revascularization is not device-specific.  [electronic resource] 

 -  The American journal of cardiology  May 2000 
 - 1060-4 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0002-9149 
<br/><br/><label>Standard No.: </label>10.1016/s0002-9149(00)00696-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Angioplasty, Balloon, Coronary<br/>Antibodies, Monoclonal--therapeutic use<br/>Atherectomy, Coronary<br/>Coronary Disease--drug therapy<br/>Female<br/>Humans<br/>Immunoglobulin Fab Fragments--therapeutic use<br/>Male<br/>Middle Aged<br/>Platelet Aggregation Inhibitors--therapeutic use<br/>Proportional Hazards Models<br/>Randomized Controlled Trials as Topic<br/>Stents<br/>Survival Analysis